clinical trial · NCT06911424
Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis
Baxis Pharmaceuticals, Inc.·phase3·recruiting·n = 400
Bacterial ConjunctivitisFusidic Acid 1%Placebo
brief summary
The purpose of this clinical trial is to demonstrate the superiority of fusidic acid 1% over placebo in adults and children with confirmed bacterial conjunctivitis and to further establish the safety profile of fusidic acid 1% for topical ocular administration.
started
Mar 21, 2025
primary completion
Mar 16, 2026
completion
Mar 23, 2026
last updated
Mar 17, 2026
official title
A Phase 3 Randomized, Multi-Center, Placebo-Controlled, Masked Study to Evaluate the Clinical Efficacy and Safety of Fusidic Acid 1% Viscous Topical Antibiotic Eye Drops for the Treatment of Suspected Bacterial Conjunctivitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol